Map Pharma (MAPP) Shares Now Down 30%
- Apple (AAPL) Earnings on Deck; Blow-Out Expected But FX Could Crimp Margin Expansion
- Procter & Gamble (PG) Misses Q2 EPS by 12c; Sees FY15 Core Earnings In-Line to Down Versus Prior Year
- Unusual 11 Mid-Day Movers 1/27: (NFEC) (SIMG) (ADXS) Higher; (STAA) (STRL) (JJSF) Lower
- Caterpillar (CAT) Misses Q4 EPS by 20c; Guides FY15 EPS Well Below the Street
- Fed Can Wait Longer on Rate Hike; Morgan Stanley Pushes Back 'Liftoff' Forecast to March 2016
After an initial move slightly lower, shares of Map Pharma (Nasdaq: MAPP) are now down more than 30 percent in Tuesday's pre-open session. The last traded was at $11.50.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Advaxis (ADXS) Defended by TheStreet's Adam Feuerstein
- U.S. Proposes to Open from Virginia to Georgia for Oil Drilling Under Draft Proposed Program (OIL) (USO)
- Cliffs Natural Resources (CLF) halted with news pending
Create E-mail Alert Related CategoriesTrader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!